Home / News / India /  Natco Pharma Q3: Net profit down 22.5% at 62.3 cr, dividend declared

Natco Pharma on Monday reported a net profit of 62.3 crore, down 22.5% as against 80.4 crore year-on-year. Revenue came in at 492.5 crore, down 12.1% as compared to 560.5 crore YoY.

The company has also declared third interim dividend of 1.25 per share, i.e., 62.50%. The date for taking on record of its shareholders eligible for the purpose of payment of the third interim dividend i.e., record date is fixed as Tuesday, the 21 February, 2023. The payment of said interim dividend will be from l March, 2023.

"The Board of Directors have approved to make the investment for an amount not exceeding Rs13 Crores (6.68% of the capital on a fully diluted basis) in Redcliffe Hygiene Private Limited," the company said in a regulatory filing.

A few days back, the drug maker said that US Food and Drug Administration (USFDA) conducted an inspection at its formulation facility in Ramky SEZ, near Visakhapatnam (Vizag), India.

Inspection was held from 30 January, 2023 to 3 February, 2023.

Post the end of the inspection, the facility received two observations, one on written production process control procedure and the other on investigation procedure.

The firm has also said that it is confident of addressing all observations within the stipulated time.

Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. 

The drug maker has manufacturing facilities in India which caters to both domestic and international markets including regulated markets such as the US and Europe.

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Recommended For You
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout